ABOUT STRATEGY+

Billy Zeilah is the Founder of Strategy+.  For over 10 years, Billy has been driving complex deals for majority of the Fortune 100 companies globally.  He is credited with over 100 closed transactions and has facilitated over $250 Billion in deal value.

Billy is seasoned in all deal types including, acquisitions, mergers, divestitures, joint ventures, spin-offs, carveouts, rollups and ringfencing strategies.  He has positioned Strategy+ as a preferred Big 4 M&A consulting partner.  Billy has advised Pfizer on the largest Pharmaceutical acquisition in history, advised on deals resulting in investments from Warren Buffet and positioned clients to save hundrends of millions in deal value through diligence and negotiations.

Matthew Logan is a dealmaker with a strong foundation in digital marketing and strategic networking. His ability to connect the right people with the right opportunities has been instrumental in driving business growth and securing high-impact transactions.

With a keen understanding of market positioning and investor engagement, Matthew leverages his  network to create value-driven partnerships and capital-raising opportunities. His expertise in branding, outreach, and deal origination has helped businesses attract strategic investors, scale effectively, and maximize their market potential.

Abdalla is a seasoned corporate executive turned associate at Strategy+. With over a decade of experience driving businesses from seven to eight figures, Abdalla has a proven track record in reshaping go-to-market strategies and building top-performing teams that consistently deliver double-digit growth. Throughout his career, he has achieved over $100 million in B2B sales and managed revenue exceeding $500 million.

Now, Abdalla leverages his extensive corporate experience to guide clients through the complexities of buying and selling businesses. He works closely with companies across various industries, including wellness and software, helping them navigate the M&A landscape with confidence.

Based in Dubai, Abdalla is also actively involved in investing in businesses, real estate, and Web 3, further solidifying his expertise in the world of strategic investments.

Dr. Zahid Moneer is a seasoned leader in healthcare investment banking, with over 15 years of experience orchestrating transformative M&A transactions in the Pharma, Biotech, and CDMO industries. His work is centered on driving strategic innovation and delivering impactful financial solutions for global healthcare clients.

Zahid's academic foundation includes a Ph.D. in Pharmacology and an Executive MBA, both from the University of Cambridge, complemented by an M.Phil in Biochemistry. He has consistently demonstrated exceptional leadership and deep sector insights, earning the trust of multinational healthcare companies.

Some of the standout deals Dr. Zahid has enabled include advising Roche on its $20.7 billion buy-back from Novartis, managing the €2.3 billion Galderma IPO, and leading Takeda’s $64 billion acquisition of Shire.

Emmanuelle is an experienced buy-side real estate private equity professional with a proven track record in high-stakes acquisitions and asset management across the U.S., European, and U.K. markets. Her portfolio spans U.S. multifamily, European hospitality, and U.K. built-to-rent developments, where she has applied strategic expertise in underwriting and managing real estate transactions across the capital stack.

Fluent in Arabic, French, and English, Emmanuelle brings valuable cross-border insights, having worked in diverse markets from Dubai to Lebanon and now London. Her deep knowledge of asset management, capital markets, and financial modeling further supports her ability to drive value creation in the EMEA region.

Dr. Arwa Aldakheel is a Subject Matter Expert in Biopharma, Energy, and Diligence, with a Ph.D. in Biomedical Engineering and over five years of experience in diagnostic testing, therapeutic target identification, and molecular biosensor development. Her expertise in nanotechnology, particularly in designing advanced molecular diagnostics using gold nanoparticles for viral detection, highlights her innovative approach to addressing biomedical challenges.

Dr. Aldakheel has also contributed to sustainable energy research at the National Institute of Standards and Technology, where she studied the semiconductor properties of advanced materials, bridging the fields of energy and biopharma. Her unique background in both clinical research and energy systems adds depth to our ability to provide specialized diligence and strategic insights to clients.